- Sponsored Content
- Gene Therapies
Rev Up AAV Genome Production
1 Min Read
Sponsored by Mirus Bio
Rev up your AAV genome production in upstream process development and manufacturing
Designed to deliver a higher AAV titer for:
Any serotype
Any transfection reagent
Any HEK 293 cell line
Any media.
Mirus Bio has developed the RevIT AAV Enhancer to further increase AAV genome titers in suspension 293-derived cells.
This novel enhancer is easily integrated into existing workflows and produces 2-4X* higher titers across a range of serotypes, cellular growth media formulations, and transfection platforms.
The RevIT AAV Enhancer can further drive down upstream manufacturing costs by lowering levels of plasmid DNA while maintaining high-quality titers.
Fill out the form below to read the full article now.
You May Also Like
Upcoming Webcasts
Jun 17 - Jun 20, 2024
Jun 17 - Jun 20, 2024
Our Biopharmaceutical School is the perfect course to gain a well-rounded understanding of the Biopharmaceutical industry. Over three days, you will understand the principle steps in the biopharmaceutical lifecycle, including: raw material selection, up and downstream processes and core technology. Additionally, you will be familiarised with the latest industry trends, including Industry 4.0, and how these are likely to impact the industry’s evolution.
Through a combination of sessions led by experts from the likes of GSK and Pall Biotech, as well as group discussions with your peers, you will learn how to bring a biopharmaceutical drug to market. Each day will be chaired by a different member of the BioProcess International Academy faculty and there will also be time for networking and Q&As with the experts.
Learn More
